AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00350337 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Post-transfection F19
Description: Dengue tetravalent Vaccine F19 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose.
Study NCT00350337 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile solution of buffered water (0.9% NaCl), U.S. FDA accepted vaccine excipient, phenol red dye(phenolsulfonphthalein, used in vaccines as a pH indicator); 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection
Study NCT04471558 — intervention group
Intervention type: OTHER
Intervention: Music
Description: A part of the RCT will be performed with music in the room. The music will be switch on just before anesthesia and off after the postoperative rest.
Study NCT03319381 — intervention group
Intervention type: BEHAVIORAL
Intervention: Following new SOPs
Description: The new SOPs comprised early whole-body CT, damage control surgery, and the use of goal-directed coagulation management and are based on the ATLS® concept, which was the strictly followed protocol before implementation of the new SOPs
Study NCT02464085 — intervention group
Intervention type: OTHER
Intervention: Longitudinal evaluation of recovery
Description: Stroke survivors will be assessed at four time frames post stroke to evaluate neuroplastic and clinical changes in arm recovery over the first 12-months post stroke.
Study NCT03786809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cimifuga Racemosa
Description: Experimental group will use 160mg of Cimifuga Racemosa for 28 days
Study NCT03786809 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients of the placebo group will use placebo once a day for 28 days
Study NCT00827073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tetracaine 0.5%
Description: betadine 5%
Study NCT00827073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2% Jelly
Description: Betadine 5%
Study NCT00831467 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV9103
Description: Over a period of 23 weeks 5 vaccinations with CV9103 will be administered.
Study NCT01862120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose D1 of interleukin-2
Description: subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
Study NCT01862120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
Study NCT01862120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose D2 of Interleukin-2
Description: subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
Study NCT01862120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose D3 of interleukin-2
Description: subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
Study NCT00289731 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TWINRIX™
Description: Intramuscular injection, 3 doses
Study NCT00289731 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: Intramuscular injection, 3 doses
Study NCT00289731 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HAVRIX™
Description: Intramuscular injection, 2 doses
Study NCT00289731 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HB VAX PRO™
Description: Intramuscular injection, 3 doses
Study NCT00289731 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaqta™
Description: Intramuscular injection, 2 doses
Study NCT01718301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir
Study NCT01718301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study NCT01718301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Study NCT01718301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Study NCT04553484 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention
Study NCT01058044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of adherence to 3 oral anticancer treatment using a  Medication Event Monitoring System 
Description: Evaluation of adherence using a  Medication Event Monitoring System  (MEMS®) for oral anticancer treatment delivered by dispensary pharmacy
Study NCT00443131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Malaria vaccine 257049
Description: Three-dose vaccination by slow intramuscular injection. Three different formulations of this vaccine are tested (without adjuvant, with adjuvant AS01B, with adjuvant AS02A).
Study NCT00887107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (nexavar)
Description: 6 months therapy with Sorafenib 800 mg/day
Study NCT04626765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T
Description: CD19 CAR-T infusion for pediatric patients with CD19 positive tumor cells
Study NCT04626765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD22 CAR-T
Description: CD22 CAR-T infusion for pediatric patients with CD22 positive tumor cells
Study NCT04626765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD 19+22
Description: CD19+22 CAR-T infusion for pediatric patients with CD19 positive and CD22 positive tumor cells
Study NCT04626765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25mg/㎡ for D-4、D-3 and D-2
Study NCT02239523 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Letter Group
Description: At time of discharge from the hospital, patients will be sent home with a letter that includes standard recommendations for evaluation and treatment for osteoporosis. This will be asked to give the letter to their primary care physician.
Study NCT02239523 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The orthopedic department will be responsible for arranging bone density testing (DEXA) and recommending specific medication after discharge. A research assistant will call monthly to encourage treatment.
Study NCT04626765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500mg/㎡ for D-3 and D-2
Study NCT01339884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: Resveratrol 1g daily (500mg twice daily) for 12 weeks Resveratrol 5 daily (2.5g twice daily) for 12 weeks
Study NCT03401970 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acellular carbohydrate diet
Description: Participants will be asked to consume 2,000 - 2,500 kcals, thereof 45 energy percent (E%) carbohydrate (up to 5 E% added sugar), 30 E% fat (10-12 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
Study NCT03401970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cellular carbohydrate diet
Description: Participants will be asked to consume 2,000 - 2,500 kcals, thereof 45 energy percent (E%) carbohydrate (up to 1 E% added sugar), 38 E% fat (10-12 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
Study NCT03401970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate high-fat diet
Description: Participants will be asked to consume 2,000 - 2,500 kcals, thereof 10 energy percent (E%) carbohydrate (up to 1 E% added sugar), 73 E% fat (30 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
Study NCT03251469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid 15mg/kg , iv, Single Dose
Description: Tranexamic Acid 15mg/kg , administered intravenously, preoperatively, in a single dose
Study NCT03251469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline, 100mg, iv, Singe dose
Description: Normal Saline, 100mg, administered intravenously, preoperatively in single dose
Study NCT02585531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic Saline 3%
Description: The treatment will be administered in the following order :~First day: 3 treatments of nebulized HS 3% 3ml of treatment with interval 20 minutes Second to fourth day: One treatment of nebulized HS 3% 3ml every 24 hours .
Study NCT02585531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine and Dexamethasone
Description: The treatment will be administered in the following order :~First day: One treatment of nebulized dexamethasone 4mg (1ml of dexamethasone 8mg/2ml) + 3ml NS, followed by two treatments of nebulized epinephrine (3 ml of epinephrine in a 1:1000 solution per treatment) with interval 20 minutes Second to fourth day: One treatment of nebulized dexamethasone 4 mg (1ml of dexamethasone 8mg/2ml) + 3ml Normal saline 0.9%, every 24 hours.
Study NCT03346668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical gabapentin
Description: topical gabapentin 6% solution
Study NCT04346758 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: lumbar plexus block
Description: Patients undergoing orthopedic procedures of the lower extremeties are going to be studied. A modified Shamrock approach of the lumbar plexus is going to be used for postoperative analgesia, using an ultrasound-guided technique combined to a nerve stimulatior. The technique is going to be assessed as for accuracy, and safety.
Study NCT03091751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BeneFIX
Description: BeneFIX is a recombinant FIX that contains nonacog alfa, reconstituted in solvent and administered as a single dose of 65-75 IU/kg.
Study NCT00497380 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arginine
Description: Oral nutritional supplement
Study NCT00497380 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Arginine
Description: Oral nutritional supplement
Study NCT01296568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2603618
Description: Administered intravenously
Study NCT01296568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered intravenously
Study NCT01296568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously
Study NCT02484794 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Outpatient Treatment
Description: Standard treatment offered by the Nova Scotia Health Authority Eating Disorder Outpatient Program varies in intensity but involves therapy groups (e.g., goal setting and skill building groups), individual contact, and meal experiences. Minimal participation in the program consists of a weekly nutritional counselling group (Nutri-Logical) and one supervised meal a week. In the nutritional counselling group, patients keep a food journal (self-monitor), set eating goals, receive feedback from a psychologist and dietitian, and share experiences with the group.
Study NCT02484794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Outpatient Treatment
Description: Standard treatment offered by the Nova Scotia Health Authority Eating Disorder Outpatient Program varies in intensity but involves therapy groups (e.g., goal setting and skill building groups), individual contact, and meal experiences. Minimal participation in the program consists of a weekly nutritional counselling group (Nutri-Logical) and one supervised meal a week. In the nutritional counselling group, patients keep a food journal (self-monitor), set eating goals, receive feedback from a psychologist and dietitian, and share experiences with the group.
Study NCT02484794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone App
Description: The smartphone app is a mobile eating disorder self-monitoring tool that incorporates discrete reminders, positive feedback, social support, summative feedback, coping skill suggestions, and linking patients with their treating clinicians (psychologist and dietician). The app is CBT-based and was designed as an alternative to paper food records for use in clinical treatment.
Study NCT04984044 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Dietary supplement:Vitamin D3~1 capsule of Vitamin D3 (40,000IU) weekly for 8 weeks with antidiabetic drug
Study NCT04984044 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule weekly for 8 weeks with antidiabetic drug
Study NCT02574975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methacholine
Description: Methacholine,inhaled cumulative dosage 2.5mg
Study NCT02574975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adenosine monophosphate
Description: Adenosine monophosphate ,inhaled cumulative dosage 40mg
Study NCT02574975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leukotriene D4
Description: Leukotriene D4,inhaled cumulative dosage 2.4 μg
Study NCT02574975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astograph Jupiter-21 airway reaction testing apparatus
Description: Methacholine bronchial provocation test was performed by using Astograph Jupiter-21 airway reaction testing apparatus
Study NCT02574975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide /formoterol
Description: budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for three months in all participants (80 Anticipated)
Study NCT01373086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFF269
Study NCT01373086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Study NCT01373086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT01373086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01373086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01123759 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Feeding low mercury fish
Description: Subjects fed 6 oz of either tilapia (low omega-3 fish) or salmon (high omega-3 fish) for 3 months. Both fish are low in mercury
Study NCT03050476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RESCAP®
Description: intravenous application before, during, and for 24 or 96 hours after heart surgery
Study NCT02567266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Adolescents (UP-A)
Description: The UP-A is an emotion-focused, transdiagnostic approach for adolescents (ages 12-18) with a primary emotional disorder. It is a developmental adaptation of the Unified Protocol, a transdiagnostic treatment for adults with emotional disorders. Clinicians present all skills in the context of the emotions most salient to presenting concerns and adolescent/caregiver conceptualizations of treatment needs, thereby personalizing treatment. The UP-A is delivered in 8-21 weekly sessions, with clinician flexibility regarding the sequencing and depth with which various sections are presented to clients and caregivers, as well as the emotions targeted during the course of the intervention.
Study NCT02567266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Outcomes Questionnaire
Description: The YOQ consists of parent- and youth-report measures of symptoms and alliance administered weekly on a tablet computer. The YOQ online system then generates reports to provide clinicians with systematic feedback about client progress, flagging critical items that have been endorsed (e.g., suicidality, hallucinations), presenting graphs of ratings over time, and providing empirically-derived alerts when clients are failing to progress or showing deterioration. Clinicians will be trained to use this feedback to modify treatment as needed, share it with families as appropriate, and use it to enhance use of supervision.
Study NCT03050476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: intravenous application before, during, and for 24 or 96 hours after heart surgery
Study NCT03869229 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular injection of ADMSC
Description: Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)- ultrasound guided intra-articular injection of at least 10 million of ADMCS per procedure, maximum four procedures (i.e. injections per joint), minimum number of cells pre protocol 40 million
Study NCT02804958 — intervention group
Intervention type: PROCEDURE
Intervention: STEMI treated with primary PCI
Description: Primary percutaneous coronary intervention was performed according to the current standard guidelines. Coronary angiography was performed using standard techniques. The use of thrombectomy devices, intravascular ultrasound, intra-aortic balloon pump, and percutaneous cardiopulmonary support was up to the operator.
Study NCT01327534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: treatment with a 60 mg loading dose prasugrel, followed by a maintenance dose of 10 mg for 30 days
Study NCT01327534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: treatment with a 600 mg loading dose clopidogrel, followed by a maintenance dose of 75 mg for 30 days
Study NCT00437489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Human Insulin (Exubera)
Description: Initial dose (mg) as per weight based formula = 0.05 x body weight (kg) TID
Study NCT00437489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Human Insulin (Exubera)
Description: Initial dose of 1mg TID of inhaled human insulin
Study NCT02449824 — intervention group
Intervention type: OTHER
Intervention: magnetic resonance imaging
Description: early MRI
Study NCT02893722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atosiban
Description: give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion in total dose of 37.5 mg is set in certain infusion rate, and complete the infusion in 3 hours.
Study NCT02893722 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion is set in the same rate with experimental group, complete the infusion in 3 hours.
Study NCT02175446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab and eribulin
Description: In this study, Bevacizumab and Eribulin are considered to be the investigational study drugs. Bevacizumab is provided as 25 mg/ml concentrate for infusion. Vials contain 100 mg of Bevacizumab in 4 ml and/or 400 mg in 16 ml. Eribulin is provided as vials containing 1 mg/2 mL Eribulin as a 500 µg/mL solution in ethanol/water
Study NCT01098448 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: scaling and root planing
Description: scaling and root planing as a single therapy
Study NCT01098448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: local tetracycline
Description: local delivery of tetracycline fibers releasing approximately 1.7 mg/tooth in all pockets >5mm
Study NCT01098448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: systemic metronidazole and amoxicillin
Description: systemic metronidazole (250 mg tid x 14) and amoxicillin (500 mg bid x 14
Study NCT01098448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: surgery
Description: periodontal surgery in residual pockets of >4mm
Study NCT01098448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: local antibiotics and systemic metronidazole and amoxicillin
Description: 1.7 mg/tooth tetracycline fiber plus metronidazole (250 mg tid x14d)and amoxicillin (500 mg bid x 14d)
Study NCT01098448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: local tetracycline and periodontal surgery
Description: local delivery of tetracycline fibers releasing approximately 1.7 mg/tooth in all pockets >5mm and periodontal surgery in residual pockets of >4mm
Study NCT01098448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: periodontal surgery and systemic metronidazole and amoxicillin
Description: surgery in residual pockets >4mm and metronidazole (250mg tidx14d) and amoxicillin (500mg bidx14d)